Genelux (GNLX) Non-Current Debt (2022)
Genelux (GNLX) posted quarterly Non-Current Debt of $1.1 million for Q4 2022.
Genelux (GNLX) Non-Current Debt (2022) Analysis & Trends
Genelux's Non-Current Debt history runs 1 years deep, the most recent figure standing at $1.1 million for Q4 2022.
- In Q4 2022, Non-Current Debt changed N/A year-over-year to $1.1 million; the TTM figure through Dec 2022 stood at $1.1 million (changed N/A YoY), while the FY2022 annual figure was $1.1 million, changed N/A from the prior year.
- Non-Current Debt for Q4 2022 stood at $1.1 million.
- The five-year high for Non-Current Debt was $1.1 million in Q4 2022, with the low at $1.1 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 546.77 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 8.96 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.97 Mn |
| 10 | Genelux | 120.53 Mn | 120.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 1.10 Mn |